Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 6Myeloid 5Other hematologic neoplasm 4Thoracic 2Plasma cell 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Lung Neoplasms 1Inhibition, Psychological 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
itacitinib × Thoracic × 1 year × Clear all
NCT02257619 2026-04-21

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 2 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 1/2 Completed
59 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡